Newly-public Immunovant announces first proof-of-concept success
Immunovant announced its first batch of proof-of-concept data for its antibody against a rare autoimmune disease, a month after its biggest rival slid one of its dogs out of the race.
In a tiny study of thyroid eye disease, 4 out of 7 patients given IMVT-1401 saw their clinical activity score improve by 2 or more points and 3 out of 7 saw their proptosis — eye protrusion — improve. There was a 65% reduction in IgG, the protein IMVT-1401 is meant to block, which was “nearly identical to modeled predictions for dosing regimen” in the trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.